Literature DB >> 8970948

The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.

S Bour1, K Strebel.   

Abstract

We have recently shown that the envelope glycoprotein of the ROD10 isolate of human immunodeficiency virus type 2 (HIV-2) has the ability to positively regulate HIV-2 viral particle release. The activity provided by the ROD10 Env was remarkably similar to that of the HIV-1 Vpu protein, thus raising the possibility that the two proteins act in a related fashion. We now show that the ROD10 Env can functionally replace Vpu to enhance the rate of HIV-1 particle release. When provided in trans, both Vpu and the ROD10 Env restored wild-type levels of particle release in a Vpu-deficient mutant of the NL4-3 molecular clone with indistinguishable efficiencies. This effect was independent of the presence of the HIV-1 envelope protein. The ROD10 Env also enhanced HIV-1 particle release in the context of HIV-2 chimeric viruses containing the HIV-1 gag-pol, indicating a lack of need for additional HIV-1 products in this process. In addition, we show for the first time that HIV-1 Vpu, as well as ROD10 Env, has the ability to enhance simian immunodeficiency virus (SIV) particle release. The effects of Vpu and ROD10 Env on SIV particle release were indistinguishable and were observed in the context of full-length SIVmac239 and simian-human immunodeficiency virus chimeras. These results further demonstrate that ROD10 Env can functionally complement Vpu with respect to virus release. In contrast, we found no evidence of a destabilizing activity of ROD10 Env on the CD4 molecule. HIV-1 and HIV-2 thus appear to have evolved genetically distinct but functionally similar strategies to resolve the common problem of efficient release of progeny virus from infected cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970948      PMCID: PMC190916     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein.

Authors:  K Strebel; T Klimkait; F Maldarelli; M A Martin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

4.  Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs.

Authors:  S Schwartz; B K Felber; E M Fenyö; G N Pavlakis
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Identification of a protein encoded by the vpu gene of HIV-1.

Authors:  E A Cohen; E F Terwilliger; J G Sodroski; W A Haseltine
Journal:  Nature       Date:  1988-08-11       Impact factor: 49.962

6.  Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome.

Authors:  Z Matsuda; M J Chou; M Matsuda; J H Huang; Y M Chen; R Redfield; K Mayer; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Genetic organization of a chimpanzee lentivirus related to HIV-1.

Authors:  T Huet; R Cheynier; A Meyerhans; G Roelants; S Wain-Hobson
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

8.  West African HIV-2-related human retrovirus with attenuated cytopathicity.

Authors:  L I Kong; S W Lee; J C Kappes; J S Parkin; D Decker; J A Hoxie; B H Hahn; G M Shaw
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

9.  Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate.

Authors:  P Kumar; H X Hui; J C Kappes; B S Haggarty; J A Hoxie; S K Arya; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

10.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.

Authors:  U Schubert; S Bour; A V Ferrer-Montiel; M Montal; F Maldarell; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  59 in total

1.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation.

Authors:  A Deora; L Ratner
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1.

Authors:  Che Ma; Francesca M Marassi; David H Jones; Suzana K Straus; Stephan Bour; Klaus Strebel; Ulrich Schubert; Myrta Oblatt-Montal; Mauricio Montal; Stanley J Opella
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

4.  HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.

Authors:  Helena Skar; Pedro Borrego; Timothy C Wallstrom; Mattias Mild; José Maria Marcelino; Helena Barroso; Nuno Taveira; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

5.  Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments.

Authors:  Markus Moll; Sofia K Andersson; Anna Smed-Sörensen; Johan K Sandberg
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

6.  A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes.

Authors:  Sayuki Iijima; Young-Jung Lee; Hirotaka Ode; Stefan T Arold; Nobuyuki Kimura; Masaru Yokoyama; Hironori Sato; Yasuhito Tanaka; Klaus Strebel; Hirofumi Akari
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

7.  Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu.

Authors:  Ankur H Shah; Bharatwaj Sowrirajan; Zachary B Davis; Jeffrey P Ward; Edward M Campbell; Vicente Planelles; Edward Barker
Journal:  Cell Host Microbe       Date:  2010-11-18       Impact factor: 21.023

8.  Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.

Authors:  Nolwenn Jouvenet; Stuart J D Neil; Maria Zhadina; Trinity Zang; Zerina Kratovac; Youngnam Lee; Matthew McNatt; Theodora Hatziioannou; Paul D Bieniasz
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

Review 9.  Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution?

Authors:  Frank Kirchhoff
Journal:  Nat Rev Microbiol       Date:  2009-03-23       Impact factor: 60.633

10.  Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs.

Authors:  Sang Ho Park; Stanley J Opella
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.